Publications

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2022

Phase 1 studies of agenT-797, a novel allogeneic invariant natural killer T cell therapy, for the treatment of patients with solid tumors or multiple myeloma, D. Stevens, et al.

Poster •November 8 - 12, 2022

Invariant natural killer T (iNKT) cell therapy (agenT-797) in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19), M. Purbhoo, et al.

Poster •November 8 - 12, 2022

Development of an allogeneic FAP-CAR iNKT product to target tumor stroma and modulate the tumor microenvironment, X. Michelet, et al.

Poster •November 8 - 12, 2022

agenT-797, a native allogeneic “off-the-shelf” invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment, S. Pakharel, et al.

Poster •November 8 - 12, 2022

MiNK-413: A Next Generation Armored Allogenic BCMA CAR iNKT Product, E. Chantzoura1, et al.

Poster •November 8 - 12, 2022

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2021

agenT-797, a native allogeneic "off-the-shelf" iNKT cell therapy shows anti-tumor activity, B. Yigit, et al.

Poster •November 10 - 14, 2021

Identification and characterization of an allogeneic iNKT-CAR Targeting BCMA, M. Purbhoo, et al.

Poster •November 10 - 14, 2021

Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-based cell therapy drug product, M. Purbhoo, et al.

Poster •November 10 - 14, 2021

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2020

AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing, B. Yigit, et al.

Poster •November 11 - 14, 2020

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2019

Discovery and characterization of the first fully-human Phosphopeptide Tumor Target-specific T cell receptor, X. Michelet, et al.

Poster •November 7 - 10, 2019

Invariant natural killer T cells as an allogeneic cell therapy platform, B. Yigit, et al.

Poster •November 7 - 10, 2019